A fund backed by investment bank Leerink Partners raised $313 million for investments in the health information technology sector. Boston-based Leerink Transformation Partners said its first fund was significantly oversubscribed compared with the $250 million it initially sought to raise. Co-founder Todd Cozzens is a medical device industry veteran and former Sequoia Capital partner; Dr. Jared […]
Leerink Partners upgrade sends Baxter shares up
Baxter (NYSE:BAX) shares gained today after analysts at Leerink Partners upgraded their view of the stock, citing its strong free cash flow and a string of “beat-‘n’raise” quarters from the Chicago-area healthcare giant. Leerink analysts Danielle Antalffy and Rebecca Wang boosted their rating on BAX shares from “market perform” to “outperform” and boosted the price target to […]
Analyst: Insulet’s drug-delivery biz a long-term growth driver
Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts. Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to […]
EuroPCR 2016 Update: TAVR innovations, FFR systems in the spotlight
UPDATED May 20, 2016, with more results out of Paris. St. Jude Medical (NYSE:STJ) announced it won CE Mark approval in the European Union for its PressureWire X Guidewire fractional flow reserve measurement system and is launching the product in Europe. The company announced the launch and clearance at the EuroPCR meeting in Paris this week. […]
Neovasc squeaks by Q2, positive on Tiara trial
Neovasc (NASDAQ:NVCN) reported 2nd quarter sales ahead of estimates, though down from 2014 and marked by growing losses, but rallied around the progress of its Tiara transcatheter mitral valve implant feasibility trial. The company’s 30-patient Tiara 1 trial has 2 study patients implanted, in addition to 5 patients implanted through compassionate use regulations. Of the 3 compassionate […]
Docs doubt ‘repless’ sales model for medical devices
A pair of high-volume orthopedists who specialize in hip and knee replacement surgeries are skeptical of generic or "repless" sales models, in which medical device companies offer lower-cost implants without a sales rep on hand to advise during the procedure.
Analyst says BSX may take CRM lead | Medtech Wall Street news for the week of September 29, 2014
Analyst: Boston Scientific could take CRM lead
Analyst: Inogen’s poised for big things with newly cleared at-home oxygen system
HRS2014: Perforations, deaths temporarily derail St. Jude’s E.U. Nanostim study
Updated May 12, 2014, at 5:30 p.m. with confirmation from St. Jude Medical.
Medtech outlook 2013: Major environmental factors for the year ahead
Wall Street analysts released their predictions for the major medical device industry trends of 2013, and the outlook isn’t much to celebrate.
